Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

Tracking major trends and clinical research in acute coronary syndrome care
Deepak Bhatt, MD, detailed several recent clinical trials that could reshape the way clinicians manage acute coronary syndrome (ACS) patients.
New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'
Deepak Bhatt, MD, believes bentracimab could be a game-changer if it gains approval. "I think it's the sort of drug that every emergency room and ICU would have to stock," he said. "A cardiac care unit would have to stock a couple of doses, as would every cath lab."
Late-breaking cardiovascular drug trials took center stage at ACC.25
Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.
Quality of care for heart patients does not improve in first year of ACO participation
Researchers tracked patient outcomes through the use of 15 performance measures related to hypertension, coronary artery disease, heart failure and atrial fibrillation.
Key takeaways from ACC.25: Advances in cardiovascular science
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.

The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

Cardiologist kills himself after starting antibiotic, prompting coroner to share concerns

The coroner is concerned that the medication's rare side effects do not receive enough attention when it is prescribed to patients.

healthcare value value-based care money dollar

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

Antithrombotic therapy after TAVR: Comparing warfarin to DAPT, SAPT

A new retrospective study from the Mayo Clinic focused on patients with no other need for anticoagulation.

FDA approves sotagliflozin, the new heart failure drug from Lexicon Pharmaceuticals

The drug, which should be available by the end of June, will be marketed under the name Inpefa.

FDA grants fast track designation to Bayer’s new drug for preventing stroke in AFib patients

The new drug, asundexian, is currently the subject of two multicenter Phase III studies—the OCEANIC-AF trial and OCEANIC-STROKE trial—focused on its safety and efficacy.

FDA expands dapagliflozin approval to cover all heart failure patients

The FDA has previously approved the SGLT2 inhibitor in patients with HFrEF, but not HFmrEF or HFpEF

Paul M. Ridker, MD, MPH, director of the Center for Cardiovascular Disease Prevention, and the Eugene Braunwald Professor of Medicine, cardiovascular medicine, Brigham and Women's Hospital, who presented the results of late-breaking study on residual inflammatory risk in contemporary statin treated patients. The study used an analyses of 31,197 patients in the PROMINENT, REDUCE-IT and STRENGTH trials.

What new data can teach cardiologists about statin use and treating inflammation

"If we do not attack the inflammation, we just are not going to get the best outcomes for our patients," one researcher told Cardiovascular Business.

Pharmaceutics

Tracking major trends and clinical research in acute coronary syndrome care

New drug reverses antiplatelet effects of ticagrelor, helping surgeons avoid a 'bloody mess'

Late-breaking cardiovascular drug trials took center stage at ACC.25

Quality of care for heart patients does not improve in first year of ACO participation

Key takeaways from ACC.25: Advances in cardiovascular science